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Abstract
Vitamin D exerts its principal actions on bone metabolism, so it has important benefits
on the skeleton. Serum 25(OH)D is directly related to bone mineral density (BMD), so
subjects with lower levels have lower BMD and higher prevalence of osteoporosis and
fractures, mainly hip and non-vertebral fractures. But, vitamin D has also many other
beneficial effects, and its deficit has been associated with a great variety of diseases, such
as  asthma,  cancer,  diabetes,  hypertension and other  cardiovascular  diseases,  some
inflammatory and autoimmune diseases, infections and some liver diseases. It is also
remarkable its direct effect on muscle strength, so patients with vitamin D deficiency
have higher risk of falls. Supplementation with vitamin D in patients with low 25(OH)D
levels has shown a favourable effect not only on bone and muscle, reducing the risk of
fracture, but also on inflammation, cell proliferation or immune system, reducing the
risk of other diseases and complications. However, observational studies are needed
with larger numbers of patients and well-designed randomized clinical trials,  with
baseline vitamin D determination and accurate monitoring to establish a cause-effect
relationship between vitamin D deficiency and some diseases.
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1. Introduction
The main vitamin D metabolite (1,25-dihydroxyvitamin D or 1,25(OH)2D) exerts its biological
actions through binding to Vitamin D receptor (VDR). VDR is a ligand-induced nuclear receptor
that regulates the expression of over 900 genes throughout the genome. 1,25(OH)2D dissociates
from serum vitamin D-binding protein (VDBP) and enters the cell and binds to and activates
the VDR, leading to the promotion and modulation of the expression of the targeted genes [1].
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VDR is found not only in the organs responsible for calcium homeostasis (bone, kidney,
intestine and parathyroid) but also in many other tissues such as immune system cells, muscle
and myocardium, which explains the extraskeletal effects of this vitamin (Figure 1) [1].
Figure 1. Principal targets and actions of vitamin D.
Serum determination of 1,25(OH)2D does not have much interest, as it has a very short half-
life and its levels are highly regulated by some hormones such as parathyroid hormone (PTH),
so subjects with vitamin D deficiency can have normal 1,25(OH)2D levels. Therefore, the best
assessment of vitamin D status is provided by serum 25(OH)D levels and thus should be the
only vitamin D assay typically performed, since its half-life is about 2 weeks.
2. Skeletal benefits of vitamin D
Vitamin D exerts its principal action on bone metabolism regulating the intestinal absorption
of calcium and bone remodeling [2]. This vitamin is essential for the normal development of
the skeleton in utero and during childhood and adolescence and also to maintain bone health
in adults. Optimal levels of vitamin D are needed to achieve a proper balance of calcium and
phosphorus for a normal bone mineralization. A longstanding vitamin D deficiency has been
associated with growth retardation and rickets in children, and osteoporosis or, in the most
severe cases, osteomalacia in adults [3].
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Serum 25(OH)D in both sexes and in all races is directly related to bone mineral density (BMD),
so that people with lower levels have lower BMD and higher prevalence of osteoporosis and
fractures [4]. This is, in part, because a sustained decrease in 25(OH)D induces a higher
secretion of PTH (secondary hyperparathyroidism), with an increase in osteoclast differentia-
tion and bone resorption over bone formation.
Levels of 25(OH)D are inversely associated with the risk of non-vertebral and hip fracture [5]
(Figure 2), so patients with lower levels of vitamin D have higher risk of fracture.
Figure 2. Risk of fracture, according to quartile of baseline 25-hydroxyvitamin D level [5].
Larrosa et al. described an association between vitamin D deficiency and the severity of hip
fracture [6]. Patients with more severe femoral neck or intertrochanteric fractures (Garden III–
IV and Kyle III–IV) have higher prevalence of vitamin D deficiency (74%) and lower levels of
25(OH)D (20 ± 15 ng/ml) than patients with less severe fractures (57% and 26 ± 21 ng/ml).
The supplementation with vitamin D has shown to improve the skeletal health reducing the
risk of fracture.
A meta-analysis conducted by Bischoff-Ferrari et al. [7] revealed that supplementation with
700–800 IU/day of vitamin D reduced up to 23% the risk of non-vertebral fractures and 26%
the risk of hip fracture, while doses <400 IU had no effect. The minimum levels of 25(OH)D to
reduce the risk of hip fracture are 29.6 ng/ml. These data have served as the basis for the
International Osteoporosis Foundation (IOF) to set as “optimal” 25(OH)D ≥ 30 ng/ml.
More recently, the same group conducted another meta-analysis involving more than 30,000
subjects and showing that only supplementation with high doses of vitamin D (800–2000 IU/
day) had an effect in the reduction in the risk of fracture (30% for hip and 14% for non-
vertebral) [5], in population over 65 years regardless of whether they were institutionalized
or not.
It is controversial whether the association of calcium with vitamin D contributes to a more
efficacy. In fact, in the last meta-analysis [5], patients supplemented with less calcium (<1000
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mg/day) had lower fracture risk than those receiving higher doses (≥1000 mg/day). Further-
more, in another meta-analysis, the authors found that supplementation with calcium alone
(without vitamin D) could even increase the risk of hip fracture. However, they recommend
taking this data with caution as participants included in some trials had been receiving more
dietary calcium than usual in the normal population. So, it cannot be ruled out that supple-
mentation with calcium is most beneficial in patients with poor dietary intake.
Despite this controversy, there is sufficient evidence of benefit of calcium supplementation
(preferably from diet) and vitamin D in osteoporosis patients, especially when receiving
antiresorptive treatment, so that clinical practice guidelines recommend the use of combined
calcium (1000–1200 mg/day) and vitamin D (800–1000 IU/day), and if not are achieved with
diet should be in the form of supplements [8].
3. Extraskeletal benefits of vitamin D
In addition to its main benefits on bone health, vitamin D has many other beneficial effects and
its deficit has been associated with a great variety of diseases.
3.1. Vitamin D and asthma
Vitamin D regulates certain key genes for lung growth during embryonic development, and
a deficiency can lead to a change in the structure and lung function.
It has been reported that the forced vital capacity in children of both sexes is strongly associated
with maternal 25(OH)D and that vitamin D deficiency in mothers is associated with an
increased incidence of asthma in children [9].
The anti-inflammatory effect of vitamin D (inhibits interleukin-6 and Tumor Necrosis Factor),
its immunomodulation of both the innate and adaptive immune systems and its potential
antimicrobial action also contribute to explain the protective effect of vitamin D in asthma [10].
Vitamin D also enhances the response of asthmatic patients to treatment and could have a
synergistic effect with steroids [11].
Some authors have even been suggested that vitamin D deficiency may be responsible in part
for the increased prevalence of asthma worldwide and that 25(OH)D levels could be a
potentially modifiable marker of severe asthma [12].
3.2. Vitamin D and cancer
The antitumour activity of vitamin D has been shown in a variety of malignancies, and these
seem to be the main mechanisms by which this action is exerted:
– Inhibition of cell proliferation. Vitamin D inhibits the phosphorylation of some proteins,
leading to inhibition of a series of genes responsible for the progression of cellular cycle [13].
– Apoptosis. Vitamin D induces cell death in some tumours through inhibition of antiapoptotic
factors and/or stimulation of proapoptotic factors, depending on the cell type [14].
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– Inhibition of angiogenesis. Vitamin D inhibits proliferation of endothelial cells and some
angiogenic factors, such as transforming growth factor alpha (TGFα), the epidermal growth
factor (EGF) and vascular endothelial growth factor (VEGF) [15]. Vitamin D also reduces the
migration and invasiveness of tumour cells.
3.2.1. Breast cancer
Breast cancer is probably the most studied cancer in regard to vitamin D status. In a cohort of
American women with breast cancer, authors found that women with optimal levels of
25(OH)D were up to 63% lower risk to present a breast cancer [16]. However, in prospective
studies, it has not succeeded in showing any relationship between 25(OH)D and breast cancer
[17]. Peppone et al. [18] in a retrospective study of 224 women with non-metastatic breast
cancer concluded that vitamin D deficiency is associated with poor prognosis and quality of
life. With these data, it seems reasonable to determine 25(OH)D levels in women with breast
cancer and supplement those with vitamin D deficiency.
3.2.2. Prostate cancer
When we analyse the association between vitamin D and prostate cancer, the literature is more
controversial. A meta-analysis published in 2014 that included 21 studies concluded that
higher concentrations of 25(OH)D were associated with an increased risk of developing
prostate cancer [19]. However, a more recent study has described a 30% higher risk in patients
with 25(OH)D in the lowest quartile than patients in the highest quartile [20].
The use of calcitriol combined with conventional treatment in patients with prostate cancer
has been proved to be effective, both in vitro and in vivo, so vitamin D enhances the antitumour
effect of the conventional treatment [21]. A clinical trial of 63 patients showed that patients
with prostate cancer treated with 4000 IU of vitamin D3 for one year had a lower tumour
progression than controls (38 versus 63%) [22]. However, to date, there is no such randomized
clinical trial with a greater number of patients that can confirm these results.
3.2.3. Colon and rectal cancer
Colon and rectal cancer have also been associated with vitamin D deficiency, especially rectal
cancer. Several meta-analysis have described an inverse association between 25(OH)D and the
incidence of colorectal cancer [23]. Patients with 25(OH)D in the highest quartile have 33%
lower risk of developing this cancer than patients with 25(OH)D in the lowest quartile [24].
At the moment, there is no evidence that vitamin D influences in the progression of colorectal
cancer, although it seems to have a protective effect on mortality [25].
3.3. Vitamin D and cardiovascular disease
Vitamin D deficiency has been associated with inflammation and endothelial and platelet
dysfunction, which favours the risk of cardiovascular complications [26].
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1,25(OH)2D has a direct action on myocardial cells, smooth muscle fibres and vascular
endothelial cells stimulating the calcium ATPase activity, promoting the calcium transfer to
the intracellular space [1]. Vitamin D also regulates blood pressure by decreasing gene
expression of renin and aldosterone synthesis. All these explain why vitamin D deficiency has
been associated with cardiovascular disease, including hypertension, ischemic heart disease
and heart failure [27].
Patients with hypertension and vitamin D deficiency have two-fold increased risk of cardio-
vascular complications [28] and up to 52% more risk of stroke [29]. In these patients, supple-
mentation with vitamin D could reduce blood pressure by decreasing the activity of renin and
angiotensin II values, although this effect has not been demonstrated in all studies.
A multicenter study [30] showed that 96% of patients with myocardial infarction (MI) had
25(OH)D < 30 ng/ml. On the other hand, it is reported that 25(OH)D is an independent predictor
of cardiovascular complications in patients with MI and that the risk is 40% higher in patients
with levels <7.3 ng/ml [31].
However, one of the effects of vitamin D is the increase in phosphate levels and a high amount
of phosphorus increases vascular calcification and, consequently, may increase morbidity and
mortalidad [32]. It is, therefore, important to keep vitamin D levels in a safe threshold, where
the benefits outweigh the risks.
3.4. Vitamin D and diabetes
Vitamin D also has receptors in pancreatic cells and exerts a regulatory action on glucose
metabolism.
A meta-analysis revealed that vitamin D supplementation in children reduces the risk of
developing type 1 diabetes (odds ratio: 0.71) [33] and also seems to prevent the development
of type 2 diabetes, as evidenced by a meta-analysis published in 2012. In this study, vitamin D
deficiency was associated with a 43% higher incidence of diabetes and 62% more progression
of prediabetes to diabetes [34].
3.5. Vitamin D in inflammatory and autoimmune diseases
Vitamin D has been linked to many other autoimmune diseases, beyond type 1 diabetes.
Some studies have reported a higher prevalence of some autoimmune diseases at higher
latitudes, suggesting that sun exposure and, therefore, the production of vitamin D may play
a role in the pathogenesis of some diseases such as type 1 diabetes, multiple sclerosis and Crohn
disease [33].
In patients with vitamin D deficiency has been described a higher incidence of Crohn’s disease,
so, in addition to its immunomodulatory effect, vitamin D promotes the function of the
intestinal barrier and stimulates the synthesis of antimicrobial peptides, all of them protective
factors for the development of inflammatory bowel disease (IBD) [35]. A prospective study
found that vitamin D deficiency could be a risk factor for developing IBD, and higher 25(OH)D
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seemed to be associated with a significant reduction in the incidence of Crohn’s disease, but
not ulcerative colitis [36].
Supplementation with vitamin D does not seem to improve significantly the clinical course of
Crohn’s disease, but it can decrease relapse in some patients.
The risk of developing multiple sclerosis is also associated with lower levels of 25(OH)D. When
we analyse the association between 25(OH)D and flare-up in patients with multiple sclerosis
before and after supplementation with 3000 IU/day of vitamin D, a strong negative association
was found between the incidence of flares and 25(OH)D levels (p < 0.0001) [37].
Vitamin D seems to have a protective role in rheumatoid arthritis (RA). In a prospective cohort
of nearly 30,000 women aged 55–69 years, authors found that the incidence of RA was 33%
lower in patients receiving more vitamin D [38].
Low vitamin D levels have also been associated with an increased incidence and/or relapses
of other autoimmune diseases such as systemic lupus erythematosus, partly due to VDR gene
polymorphisms [39].
3.6. Vitamin D and infections
Vitamin D has a protective role against infections by stimulating the production of cathelicidin
(antimicrobial peptide) and modulating the production of cytokines and the inflammatory
cascade during the infection [40], so vitamin D deficiency has also been associated with an
increased risk of infections, especially those of the respiratory tract, including tuberculosis [41].
3.7. Vitamin D and liver disease
It has also been suggested that vitamin D may play a role in the development of some chronic
liver diseases such as non-alcoholic fatty liver disease, cholestatic disease and autoimmune
liver disease; and that supplementation with vitamin D could improve the patient response to
antiviral therapy in hepatitis C [42].
3.8. Vitamin D and falls
Vitamin D has a direct effect on muscle strength through its action on specific receptors on the
muscle.
Vitamin D deficiency has been associated with type II muscle fibres atrophy, which leads to
impaired muscle function and disability, increasing the risk of falls, especially in the elderly
[43].
Supplementation with vitamin D at doses of 700–1000 IU/day reduces the risk of falls up to
34%, contributing to the antifracture effect [44]. This reduction in the risk of falls seems
apparent already in the first 6 months of treatment with vitamin D.
Levels of 25(OH)D > 24 ng/ml are needed to achieve a significant reduction in the risk of falls
(relative risk [RR]: 0.77; confidence interval [CI]: 95%, 0.65–0.90), while lower values do not
seem sufficient (RR: 1.35; 95% CI: 0.98–1.84) [45].
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4. Summary and conclusions
Besides the well-known benefits on the skeleton, especially as regards on reducing the risk of
non-vertebral and hip fracture, vitamin D also has other favourable effects on many organs.
Its immunomodulatory, anti-inflammatory, antitumour and antimicrobial effects, as well as
their effects on glucose metabolism, cardiovascular system and muscle, are remarkable.
Although the association of vitamin D deficiency with many diseases, as well as the benefits
of supplementation, seems clear, it is not easy to establish a cause-effect relationship. Obser-
vational studies with larger numbers of patients and well-designed randomized clinical trials
are needed with accurate determination and close monitoring of vitamin D.
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